Add BrightSurf on Google Email

Hepatitis drug increases antibiotic potency, limits antibiotic resistance

A study led by New York University researchers found that the FDA-approved hepatitis C treatment telaprevir can increase bacterial sensitivity to antibiotics and reduce antibiotic resistance. The antiviral blocks the function of essential proteins in bacteria, revealing an opportunity to repurpose the drug to use alongside antibiotics.

SourceNew York University·JournalCell Chemical Biology·TypeExperimental study·DateNov 23, 2021

EU/EEA during COVID-19 pandemic: Largest annual decrease in antibiotic use in the community in two decades

The European Union and European Economic Area saw a significant decline in antibiotic consumption in 2020, with a 18% decrease compared to 2019. This decline was largely attributed to the COVID-19 pandemic, which led to reduced primary care consultations for mild infections.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateNov 18, 2021

New group of antibacterial molecules identified

Researchers at Karolinska Institutet have discovered a new group of small antibacterial compounds that inhibit the formation of bacterial cell walls, showing promise against antibiotic-resistant strains. The molecules work by binding to lipid II, a crucial molecule for bacterial cell wall construction.

SourceKarolinska Institutet·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 17, 2021

A way in: Newly-identified state in bacteria has major implications for antibiotic treatment and resistant strains

Researchers at Hebrew University of Jerusalem discover a 'disrupted' state in bacteria that resists current antibiotics, requiring new pharmacological agents to combat. The breakthrough model predicts bacterial population responses to treatments, offering avenues for better treatments against cancer cells.

SourceThe Hebrew University of Jerusalem·JournalNature·TypeExperimental study·DateNov 17, 2021

Warning over antibiotic-resistant bacteria

A study by Anglia Ruskin University has identified potentially dangerous Pseudomonas bacteria in 21% of wild bird faeces collected from locations near the River Cam. The bacteria, which can be passed on to humans through cross-contamination, were resistant to multiple antibiotics.

SourceAnglia Ruskin University·JournalEcology and Evolution·DateNov 17, 2021

Same day test identifies secondary infections in COVID-19 patients

A rapid same-day test has been developed to identify secondary infections in COVID-19 patients on intensive care, allowing for targeted antibiotic treatment and reduced risk of antimicrobial resistance. The test uses nanopore sequencing technology to analyze bacterial and fungal pathogens present in patient samples.

SourceNIHR Biomedical Research Centre at Guy’s and St Thomas’ and King’s College London·JournalGenome Medicine·TypeRandomized controlled/clinical trial·DateNov 16, 2021

Penicillin significantly reduces rheumatic heart disease progression in children

A new study found that regular antibiotic treatment with penicillin significantly reduced the risk of underlying rheumatic heart disease progression in children and adolescents. Early screening was critical in preventing serious disease progression and death in young children.

SourceMurdoch Childrens Research Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 13, 2021

Going for gold to reduce antibiotic resistance

Research identifies way of using nanoparticles to target and disrupt bacterial cells, making them more susceptible to standard antibiotic treatments. Laboratory studies show a strong effect in killing a range of bacteria, including some linked to hospital-acquired infections.

SourceUniversity of Leeds·JournalChemical Science·TypeExperimental study·DateNov 9, 2021

Combating antibiotic resistance

The need for new antibiotics is critical due to rising antibiotic resistance, which kills over 35,000 people annually in the US. Research by Harvard Medical School aims to develop better antibiotics by targeting essential bacterial proteins.

SourceHarvard Medical School·JournalScience·DateNov 3, 2021

Antibiotics for appendicitis: CODA study findings finalized

The Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial found that nearly 7 in 10 patients with antibiotics avoided an appendectomy within three months. By four years, just under 50% had the surgery, suggesting both treatments are safe and valuable to patients differently based on unique symptoms and circumstances.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateOct 25, 2021

New nanomaterial for treatment of skin infections

Researchers at IOCB Prague have developed a novel antibacterial material called NANO-LPPO that can prevent infection and facilitate treatment of skin wounds. The material combines lipophosphonoxins with a nonwoven nanotextile, which releases active substances in response to bacterial presence.

New research provides compelling evidence of the connection between AMR surgical-site infections and arthropods

A new study by Oxford academics found that approximately 20% of flies and cockroaches carry carbapenem resistance, while 70-80% carry extended spectrum cephalosporin resistance. Climate change could lead to a doubling of insect populations and an increase in the global spread of antibiotic resistance.

SourceUniversity of Oxford·JournalNature Microbiology·TypeRandomized controlled/clinical trial·DateSep 30, 2021

Researchers explore promising treatment for MRSA ‘superbug’

A new study from Cornell University has found that the antimicrobial properties of certain stem cell proteins can effectively reduce the viability of methicillin-resistant Staphylococcus aureus (MRSA) in skin wounds. The treatment also stimulates the surrounding skin cells to build up a defense against the bacterial invader.

SourceCornell University·JournalStem Cells Translational Medicine·DateSep 16, 2021

Ground-breaking bacteria-killing viruses unite with antibiotics to fight devastating antibiotic-resistant bacteria

Scientists have developed a new therapy that combines bacteriophages with antibiotics to treat antibiotic-resistant infections, specifically targeting Mycobacterium abscessus. The treatment, using the bacteriophage 'Muddy', showed significant improvement in survival rates and severity of infections when paired with rifabutin, demonstra...

SourceThe Company of Biologists·JournalDisease Models & Mechanisms·TypeExperimental study·DateSep 16, 2021

Combining melatonin with vancomycin reduces kidney failure

A study found that adding melatonin to vancomycin treatment significantly reduces acute kidney injury in hospitalized patients, alleviating oxidative stress and restoring kidney function. The findings could lead to larger therapeutic breakthroughs and pave the way for further clinical studies.

SourceRutgers University·JournalAntimicrobial Agents and Chemotherapy·TypeData/statistical analysis·DateSep 15, 2021

Probotic-containing yogurt protects against microbiome changes that lead to antibiotic-induced diarrhea

A randomized clinical trial found that yogurt containing Bifidobacterium lactis BB-12 protected against harmful changes in the gut microbiome after antibiotic administration. The study also showed that levels of beneficial short-chain fatty acid acetate returned to baseline within 30 days.

SourceUniversity of Maryland School of Medicine·JournalNutrients·TypeRandomized controlled/clinical trial·DateSep 14, 2021

Antibiotics increase the risk of colon cancer

Researchers found a significant link between antibiotic use and an increased risk of developing colon cancer within five to ten years. The risk was highest for those taking antibiotics for over six months, with a 17% greater likelihood of colon cancer in the ascending colon compared to non-users.

SourceUmea University·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateSep 1, 2021

CHOP researchers develop coating for endotracheal tubes that releases antimicrobial peptides

Researchers created a polymer coating that releases Lasioglossin-III, an AMP with broad-spectrum antibacterial activity, targeting specific infectious bacteria and preventing airway complications. The coating demonstrated significant antibacterial activity and prevented bacterial adherence to the tube.

SourceChildren's Hospital of Philadelphia·JournalThe Laryngoscope·TypeExperimental study·DateAug 4, 2021